The Janus kinase (JAK) family is a group of tyrosine kinases that is coupled to the cytoplasmic signal transducer of transcription (STAT) factors and mediates cytokine signaling. Four different JAKs, namely JAK1, JAK2, JAK3, and tyrosine kinase, harbor different cytokine receptors relevant to the pathophysiology of many inflammatory skin diseases, including atopic dermatitis (AD), psoriasis, and alopecia areata. Therefore, several JAK inhibitors have reached the market or are still in clinical development as a novel therapeutic option for inflammatory diseases.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: